Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: J Am Acad Dermatol. 2020 May 13;83(5):1341–1348. doi: 10.1016/j.jaad.2020.05.007

Fig 3.

Fig 3.

Patient-based outcome measures were significantly reduced at weeks 12 and 24 of brodalumab therapy compared with baseline scores. Patient-rated disease severity (A) Visual Analogue Scale scores, (B) mean DLQI scores, (C) mean Beck Depression Inventory scores, and (D) Mean PHQ-9 scores were reduced significantly at weeks 12 and 24. DLQI, Dermatology Life Quality Index; PHQ-9, Patient Health Questionnaire-9.